Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
出版年份 2021 全文链接
标题
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages JCO.21.01210
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2021-07-27
DOI
10.1200/jco.21.01210
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia
- (2021) John C. Byrd et al. BLOOD
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2020) Paolo Ghia et al. JOURNAL OF CLINICAL ONCOLOGY
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
- (2020) Jeff P Sharman et al. LANCET
- A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY
- (2020) Constantine S. Tam et al. BLOOD
- Ibrutinib-Mediated Atrial Fibrillation Due to Inhibition of CSK
- (2020) Ling Xiao et al. CIRCULATION
- Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis
- (2019) Daniel Caldeira et al. PLoS One
- Long-term follow-up of the RESONATE™ phase 3 trial of ibrutinib versus ofatumumab
- (2019) John C. Byrd et al. BLOOD
- Targeting BTK in CLL: Beyond Ibrutinib
- (2019) David A. Bond et al. Current Hematologic Malignancy Reports
- Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
- (2019) Thomas J. Kipps et al. Clinical Lymphoma Myeloma & Leukemia
- Hypertension and incident cardiovascular events following ibrutinib initiation
- (2019) Tyler Dickerson et al. BLOOD
- Cardiovascular Toxicities Associated With Ibrutinib
- (2019) Joe-Elie Salem et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
- (2019) Jan A. Burger et al. LEUKEMIA
- Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
- (2019) John C. Byrd et al. BLOOD
- Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
- (2018) Susan O’Brien et al. BLOOD
- Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
- (2017) Jennifer R. Brown et al. HAEMATOLOGICA
- Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
- (2017) Tjeerd Barf et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib
- (2017) Khai Li Chai et al. LEUKEMIA & LYMPHOMA
- Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
- (2017) Jennifer R. Brown et al. HAEMATOLOGICA
- Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience
- (2016) A. R. Mato et al. BLOOD
- Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells
- (2016) Viralkumar Patel et al. CLINICAL CANCER RESEARCH
- Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth
- (2016) Jun Chen et al. MOLECULAR CANCER THERAPEUTICS
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
- (2014) J. R. McMullen et al. BLOOD
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
- (2012) M. F. M. de Rooij et al. BLOOD
- Treatment of elderly patients with chronic lymphocytic leukemia
- (2009) Barbara Eichhorst et al. LEUKEMIA & LYMPHOMA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now